GLSI · Greenwich LifeSciences, Inc. · Financials
Substantial doubt about the company's ability to continue as a going concern.
“The Company has prepared its financial statements on a going concern basis, which assumes that the Company will realize its assets and satisfy its liabilities in the normal course of business. However, the Company has incurred net losses since its inception and has negative operating cash flows. These circumstances raise substantial doubt about the Company's ability to continue as a going concern within one year after the date these financial statements are issued.”View the 10-Q filed Aug 11, 2026
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| $20.3M | $17.22M | $15.48M | $7.7M | $6.48M | $3.56M | $1.06M | $2.61M | |
| $2.36M | $2.23M | $2.16M | $1.63M | $1.56M | $1.04M | $806.19K | $818.89K | |
| $22.66M | $19.45M | $17.64M | $9.33M | $8.04M | $4.6M | $1.86M | $3.43M | |
| -$22.66M | -$19.45M | -$17.64M | -$9.33M | -$8.04M | -$4.6M | -$1.86M | -$3.43M | |
| $186.64K | $89.7K | $223.01K | $436.06K | $215.02K | $27.37K | $832 | — | |
| -$22.47M | -$19.36M | -$17.41M | -$8.89M | -$7.83M | -$4.57M | -$1.86M | -$3.43M | |
| USD/shares | -$1.60 | -$1.43 | -$1.34 | -$0.69 | -$0.61 | -$0.35 | — | — |
| USD/shares | -$1.60 | -$1.43 | -$1.34 | -$0.69 | -$0.61 | — | — | — |
| shares | — | 13.53M | 13.01M | 12.85M | — | 12.94M | 9.5M | 2.26M |
| shares | — | 13.53M | 13.01M | 12.85M | 12.91M | 12.94M | 9.5M | 2.26M |
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 330 similar-size Biotechnology companies (of 560 listed).